Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 Study of Imetelstat vs Best Available Therapy in Relapsed/Refractory Intermediate-2 or High-risk Myelofibrosis
2020-003288-24Phase 3Active
- Sponsor
- Geron Corporation
- Start
- Dec 2020
- Modality
- Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, MicroRNA (miRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of imetelstat in myelofibrosis (MF) (2 arms), sponsored by Geron Corporation. Primary endpoint: overall survival. Started Dec 2020; status: active.
02
Drugs
imetelstat
03
Conditions
myelofibrosis (MF)
Beyond the preview
Go deeper on 2020-003288-24.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-003288-24.